Oligodendroglioma Clinical Trials

14 recruiting

Oligodendroglioma Trials at a Glance

18 actively recruiting trials for oligodendroglioma are listed on ClinicalTrialsFinder across 6 cities in 10 countries. The largest study group is Phase 2 with 5 trials, with the heaviest enrollment activity in Houston, Boston, and Heidelberg. Lead sponsors running oligodendroglioma studies include Dartmouth-Hitchcock Medical Center, Henan Provincial People's Hospital, and Columbia University.

Browse oligodendroglioma trials by phase

Treatments under study

About Oligodendroglioma Clinical Trials

Looking for clinical trials for Oligodendroglioma? There are currently 14 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Oligodendroglioma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Oligodendroglioma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 118 of 18 trials

Recruiting
Not Applicable

PRO-GLIO: PROton Versus Photon Therapy in IDH-mutated Diffuse Grade II and III GLIOmas

Diffuse Astrocytoma, IDH-MutantOligodendrogliomaOligodendroglioma, Anaplastic
Oslo University Hospital225 enrolled1 locationNCT05190172
Recruiting
Phase 1

A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma

GlioblastomaAnaplastic AstrocytomaAnaplastic Oligodendroglioma+2 more
University of Nebraska24 enrolled1 locationNCT05698524
Recruiting
Phase 3

SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

GliomaAstrocytoma, IDH-Mutant, Grade 2Astrocytoma, Grade IV+5 more
Nuvation Bio Inc.365 enrolled45 locationsNCT05303519
Recruiting
Phase 2

All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma

GliomaOligodendrogliomaAstrocytoma+1 more
Stephen Bagley, MD, MSCE55 enrolled1 locationNCT05345002
Recruiting
Phase 3

A Clinical Study to Improve Brain Function and Quality of Life of Patients With Newly Diagnosed Brain Tumors (Gliomas).

Oligodendroglioma
University Hospital Heidelberg406 enrolled19 locationsNCT05331521
Recruiting
Phase 3

A Randomized Trial of Delayed Radiotherapy in Patients Low-grade Oligodendrogliomas Requiring a Treatment Other Than Surgery

OligodendrogliomaLow-grade Oligodendroglioma1p19q Codeletion
Hospices Civils de Lyon280 enrolled26 locationsNCT04702581
Recruiting
Phase 2

Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas

GlioblastomaOligodendrogliomaWHO Grade III Glioma+6 more
M.D. Anderson Cancer Center40 enrolled1 locationNCT04623931
Recruiting
Phase 1

Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms

Central Nervous System NeoplasmsGlioblastomaOligodendroglioma+20 more
Jazz Pharmaceuticals102 enrolled1 locationNCT04541082
Recruiting
Phase 1Phase 2

Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age

Glioblastoma MultiformeOligodendrogliomaDiffuse Intrinsic Pontine Glioma+5 more
University of Miami20 enrolled1 locationNCT05956821
Recruiting
Not Applicable

HOBSCOTCH-CA (HOme-Based Self-management and COgnitive Training CHanges Lives in Brain CAncer)

Brain NeoplasmsBrain TumorCognitive Dysfunction+9 more
Dartmouth-Hitchcock Medical Center125 enrolled1 locationNCT06930846
Recruiting

Amino Acid PET-based Response Assessment in IDH-mutant Gliomas (APPEAR)

IDH-mutant Glioma (Oligodendroglioma, Astrocytoma)
LMU Klinikum100 enrolled2 locationsNCT07159607
Recruiting
Not Applicable

FearLess in NeuroOncology

CaregiverGlioblastoma (GBM)Oligodendroglioma+2 more
Virginia Commonwealth University112 enrolled1 locationNCT06989086
Recruiting
Early Phase 1

Implantable Microdevice In Primary Brain Tumors

GlioblastomaAstrocytomaGrade II Glioma+5 more
Oliver Jonas12 enrolled1 locationNCT04135807
Recruiting
Not Applicable

Adaptive Radiotherapy and MRIs Based on Patients With Newly Diagnosed High-Grade Glioma

GlioblastomaAnaplastic AstrocytomaAstrocytoma+1 more
Columbia University20 enrolled1 locationNCT06108206
Recruiting
Phase 2

Study of Olutasidenib and Temozolomide in HGG

Metastatic Brain TumorIDH1 MutationAstrocytoma, Grade IV+16 more
Rigel Pharmaceuticals60 enrolled18 locationsNCT06161974
Recruiting

Proton Therapy Research Infrastructure- ProTRAIT- Neuro-oncology

GerminomaMeningiomaAdenoma+9 more
Maastricht Radiation Oncology1,500 enrolled3 locationsNCT04648462
Recruiting
Phase 2

Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse Oligodendroglioma

Oligodendroglioma
Henan Provincial People's Hospital80 enrolled1 locationNCT05512351
Recruiting
Phase 3

Efficacy of Post-radiation Adjuvant Temozolomide Chemotherapy in Residue Low-grade Glioma

OligodendrogliomaAstrocytomaOligodendroastrocytoma
Sun Yat-sen University290 enrolled1 locationNCT01649830